| Slideshows | December 18, 2019
8 advocates speak out for early introduction of Big Eight allergenic foods With a vast potential for benefit, studies show this benefit is likely and of no risk at all, and the analysis overwhelmingly favors a universal recommendation for the early introduction of the Big Eight allergenic foods to infants. It should come as no surprise, then, that despite the measured AAP recommendation, numerous experts and institutions advocate this very approach. Here's what 8 have to say.
Newsletter Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Subscribe
November 17th, 2026 The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
November 17th, 2026 The US lost measles elimination status after 26 years; CDC and partners plan to regain it via MMR vaccination and $100M in health department funding.
November 17th, 2026 At ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.
November 17th, 2026 US preterm birth rate held at 10.4%, earning a fifth straight D+ from March of Dimes; maternal deaths fell, but racial disparities persist.
November 16th, 2026 In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.
November 16th, 2026 Data presented at NSGC 2026 tie maternal autoantibody combinations to a non-genetic autism subtype with high recurrence risk in later-born siblings.
November 16th, 2026 Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.
November 16th, 2026 Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.